Paraneoplastic cerebellar ataxia, also known as paraneoplastic cerebellar degeneration, is one of the wide array of paraneoplastic neurological syndromes in which neurological symptoms are indirectly caused by an underlying malignancy, most commonly gynecological, breast, or lung cancer or Hodgkin's lymphoma. We describe a patient with severe cerebellar dysfunction attributed to a paraneoplastic neurological syndrome. The case highlights the need to look for paraneoplastic syndromes-both to discover malignancies early, at a treatable stage, and, as in our case, to address very distressing symptoms for the patient's relief even if the malignancy is not curable.
T he neurologic manifestations seen in cancer patients are mostly the consequence of direct tumor invasion of the nervous system or metastases. Other common causes of neurologic symptoms include neurotoxicity from cancer treatment, infections, and vascular or metabolic disorders. In less than 1% of cancer patients, an autoimmune response develops that targets normal neural tissues, which is termed paraneoplastic neurologic syndrome (PNS) (1, 2) . Autoimmune neuronal degradation is believed to occur when systemic malignancies express proteins, called onconeural antigens, that are made only in neurons (3) . Although no studies to date have conclusively proven that paraneoplastic antibodies are pathogenic, they are still useful markers of autoimmunity that categorize the PNS subtypes (1) . We present a case of paraneoplastic cerebellar ataxia (PCA) associated with anti-Yo antibody (anti-Purkinje cell antibody) due to an underlying gynecologic malignancy.
CASE DESCRIPTION
A 67-year-old white woman presented with a 3-day history of headache, severe imbalance, nausea, and binocular double vision limiting her mobility. Two weeks earlier, she had been diagnosed with a left 4 cm adnexal mass following a 6-week history of pelvic pain. She was known to have hypertension, coronary artery disease, aortic stenosis (mild), left ear cholesteatoma, and mastoiditis. Neurological examination revealed intact language and cognition, signifi cant bilateral diplopia and nystagmus worse to the right, bilateral dysmetria worse on the left, and broad-based gait ataxia. No focal weakness or change in muscle tone was noted. Deep tendon refl exes were brisk at all sites, and the plantar refl exes were downgoing on the right and upgoing on the left. Routine laboratory work was unremarkable. A biopsy of the recently discovered pelvic mass disclosed a poorly diff erentiated adenocarcinoma of Mullerian origin. A computed tomography (CT) scan of the chest, abdomen, and pelvis revealed mediastinal lymphadenopathy.
Th e patient was started on chemotherapy with carboplatin and paclitaxel. A serum paraneoplastic panel was positive for anti-Yo antibody with a high titer ( Table 1) . Cerebrospinal fl uid (CSF) examination showed lymphocytic pleocytosis, high protein, and positive anti-Yo antibodies (Table 2) . Magnetic resonance imaging (MRI) of the head on admission showed no evidence of metastatic disease. MRI done 10 days after admission, however, showed enhancement along the bilateral cerebellar sulci. A diagnosis of anti-Yo-associated PCA was made, and the patient was started on high-dose methylprednisolone and intravenous immunoglobulin (IVIG) at 2 g/kg given over a period of 3 days along with her chemotherapy drugs. Her headache resolved, and her diplopia and dysmetria were slightly improved. Th e patient was transferred to a rehabilitation facility for continuation of palliative chemotherapy.
DISCUSSION
PNS are rare neurological syndromes that are not the consequence of direct invasion, metastasis, or side eff ects of cancer treatment (2) . PNS can aff ect any level of the nervous system (Table 3) . Th ey can aff ect a single site, as in Lambert-Eaton myasthenic syndrome, a single cell type, as in PCA, or multiple areas, as in paraneoplastic encephalomyelitis. Th e association of many PNS with specifi c antibodies that recognize onconeural antigens suggests that PNS may be due to an initial autoimmune response against the tumor (1). However, one antibody can be associated with diff erent neurological syndromes, and one syndrome can present with diff erent antibodies as well (1) . Th e antibodies are specifi c for the malignancy rather than being specifi c for a neurological syndrome (2). One of the most common PNS is PCA (4). PCA results in rapid (less than 12 weeks) development of severe pancerebellar dysfunction (1, 2). Since it can precede the presentation of neoplasms by several months to a year, a high index of Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes suspicion is required (2) . Neurologic symptoms are the fi rst manifestation of the tumor in about 70% of PNS patients (4) . Th e diagnostic possibility should be considered in the setting of a family history of cancer or autoimmune disorder, subacute presentation, neuraxis involvement at multiple levels, and an insidious progression of the neurological condition with no clear alternative diagnosis (2) . Th e hallmark of PCA is severe loss of cerebellar Purkinje cells with relative preservation of other cerebellar neurons and the presence of infl ammatory infi ltrates in the cerebellar cortex, deep cerebellar nuclei, and inferior olivary nuclei (1, (4) (5) (6) . Prodromal symptoms, such as viral-like illness, dizziness, nausea, and vomiting, are followed acutely to subacutely by gait unsteadiness progressing rapidly to ataxia, diplopia, often nystagmus, dysarthria, and dysphagia (4, 5) . Blurry vision, oscillopsia, transient opsoclonus, and cognitive impairment may be present (4, 5) .
CT and MRI studies are initially normal in most cases, although some have transient diff use cerebellar hemispheric enlargement or cortical meningeal enhancement, with eventual cerebellar atrophy (1, 4) . Fluorodeoxyglucose positron emission tomography may show cerebellar hypermetabolism in early stages followed by hypometabolism as cerebellar atrophy develops (4). CSF often shows nonspecifi c abnormalities, such as mild to moderate lymphocytic pleocytosis, increased protein, a high IgG index, and CSF-specifi c oligoclonal bands in approximately 60% of PCA patients (2, 4, 5) . Intrathecal synthesis of autoantibodies is a frequent fi nding in PCA patients with anti-Yo antibody (7) . Only 60% to 70% will have detectable antibodies in their serum or CSF (2).
April 2015 It is preferable to look for the entire range of paraneoplastic antibodies, as nine specifi c antineuronal antibodies are associated with PCA (2, 6) ( Table 4) . Purkinje cell cytoplasmic antibody type 1 (PCA-1), also known as anti-Yo, is highly specifi c and the most frequently detected autoantibody in PCA (5, 8) . Th e presence of paraneoplastic antibodies can direct the care team towards a tumor search using a CT scan of that region (1) (Figure 1 ). Most cases of anti-Yo PCA occur in women over 60 years (5) .
PCA treatment includes tumor treatment, immunotherapy, and supportive therapy. Treating the tumor as soon as possible is the best approach for stabilization or symptom improvement with or without immunotherapy (2, 4) . Immunotherapy includes steroids, IVIG, plasmapheresis, cyclophosphamide, azathioprine, and rituximab (2) . In most cases of PCA, the neurological symptom has stabilized by the time treatment is started, meaning that Purkinje cell damage and neuronal loss have most probably already occurred (5) . Multiple studies have shown that patients with anti-Yo antibodies have a worse neurologic prognosis, with most becoming bedbound within 3 months of diagnosis, compared with PCA patients with other antibody types (5, 9) . However, immunotherapy has been reported to be eff ective in some cases, and hence a trial of IVIG, steroids, or plasmapheresis is indicated (1). Our patient with anti-Yo-associated PCA experienced clinical improvement in some of her neurologic symptoms and stabilization of other symptoms with high-dose steroids and IVIG. However, her relief was partial since her primary cancer was advanced and treatments were limited. Generally, it is the tumor progression and not the neurological disease that causes death in PCA patients (5). Nevertheless, in our patient, the PNS signifi cantly aff ected her quality of life, while the malignancy was largely asymptomatic. Despite successful treatment of the primary tumor in many cases, paraneoplastic symptoms often continue to negatively impact the patients' quality of life more so than the underlying tumor (9) . Th is signifi es the importance of early diagnosis, as delays in the start of treatment can lead to rapid progression and irreversible neurological damage (2) .
